Data and KOL network

Build models from the highest quality data.

Tip arrowTip arrowTip arrow

Challenges

Our federated learning software and research network provide us with unrivaled access to high-quality, high-value data.

GDPR and GCP compliant data

Our federated learning technology allows privacy-preserving remote access and computing of pseudonymized data.

Privileged and curated high-quality data access

Our collaborative relationships with medical experts and data providers ensure access to continuously updated top-quality data.

Accelerated data access

Our world-class Data Network provides accelerated data access compared to standard practices.

Rich longitudinal follow up

Our longitudinal datasets follow outcome and treatment response data from patient diagnosis to death/long-term cure.

High dimensional & multimodal datasets

Our multimodal datasets include tabular, clinical, histology, genomic and imaging data.

GDPR and GCP compliant data

Our federated learning technology allows privacy-preserving remote access and computing of pseudonymized data.

Privileged and curated high-quality data access

Our collaborative relationships with medical experts and data providers ensure access to continuously updated top-quality data.

Accelerated data access

Our world-class Data Network provides accelerated data access compared to standard practices.

Rich longitudinal follow up

Our longitudinal datasets follow outcome and treatment response data from patient diagnosis to death/long-term cure.

High dimensional & multimodal datasets

Our multimodal datasets include tabular, clinical, histology, genomic and imaging data.

arrow

Our growing patient data and KOL network

Data access

tip-arrow

Expand your access to high quality multimodal data and accelerate research

Join our Federated Data Network

To empower your teams to:

Identify patient subgroups

Develop diagnostic tools to efficiently identify specific patient subgroups.

Discover biomarkers

Identify precise disease biomarkers of survival, recurrence and response to treatment from multimodal datasets.

Accelerate clinical trials

Develop standard analysis and novel AI-based analysis methods to accelerate and optimize your clinical trials.

Collaborate at scale

Foster unprecedented data collaborations that are secure and regulatory compliant via our federated learning software, Substra.

Identify patient subgroups

Develop diagnostic tools to efficiently identify specific patient subgroups.

Discover biomarkers

Identify precise disease biomarkers of survival, recurrence and response to treatment from multimodal datasets.

Accelerate clinical trials

Develop standard analysis and novel AI-based analysis methods to accelerate and optimize your clinical trials.

Collaborate at scale

Foster unprecedented data collaborations that are secure and regulatory compliant via our federated learning software, Substra.

Collaboration in healthcare

Owkin is proof that collaboration in healthcare could make precision medicine a reality.

Through data access and KOL insight, we’ve created breakthrough models

Professor Fabrice André, MD, PhD

Professor Fabrice André, MD, PhD

Director of Research Gustave Roussy

"Owkin is leading the use of AI for prediction and drug discovery in cancer. It has developed methods to detect predictive signals that the human brain can’t. We developed a pathology tool to predict relapse in early stage breat cancer patients in one year, while we struggled for many years to do it with other teams."

Professor Francoise Galateau Salle, MD, PhD

Professor Francoise Galateau Salle, MD, PhD

Head of MESOPATH in the Department of Biopathology Cancer Centre Léon Bérard

“We had a wonderful experience with Owkin…they created an algorithm and the results exceeded our expectations. They were able to identify details from the histology slides that we knew about but had never previously recognized as significant prognostic indicators or biomarkers of treatment decisions.”

Professor William R. Jarnigan , MD

Professor William R. Jarnigan , MD

Chief of Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center

“I am excited to be part of this cutting-edge research collaboration that will have a positive impact on how clinicians evaluate and treat patients with intrahepatic cholangiocarcinoma, and potentially other cancers, as well.”

Professor Fabrice André, MD, PhD

Professor Fabrice André, MD, PhD

Director of Research Gustave Roussy

"Owkin is leading the use of AI for prediction and drug discovery in cancer. It has developed methods to detect predictive signals that the human brain can’t. We developed a pathology tool to predict relapse in early stage breat cancer patients in one year, while we struggled for many years to do it with other teams."

Professor Francoise Galateau Salle, MD, PhD

Professor Francoise Galateau Salle, MD, PhD

Head of MESOPATH in the Department of Biopathology Cancer Centre Léon Bérard

“We had a wonderful experience with Owkin…they created an algorithm and the results exceeded our expectations. They were able to identify details from the histology slides that we knew about but had never previously recognized as significant prognostic indicators or biomarkers of treatment decisions.”

Professor William R. Jarnigan , MD

Professor William R. Jarnigan , MD

Chief of Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center

“I am excited to be part of this cutting-edge research collaboration that will have a positive impact on how clinicians evaluate and treat patients with intrahepatic cholangiocarcinoma, and potentially other cancers, as well.”